As a preeminent contract antibody development company, Creative Biolabs offers high-quality in vitro diagnostic (IVD) antibody development services targeting a wide range of biomarkers. Here, we focus on the Lp-PLA2 marker. We are committed to providing the highest quality of custom services and products at the most reasonable prices.
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase (PAF-AH), is a member of phospholipase A2 superfamily encoded by the PLA2G7 gene which is formed by 12 exons and located on chromosome 6p21.2 to 12 in human. Lp-PLA2 is a Ca2+-independent protein with a molecular weight of 45 kDa that is composed of 441 amino acid. In general, Lp-PLA2 is produced in the cells associated with atherosclerosis, including mast cells, T cells, macrophages, and lymphocytes. As one type of PAF acetylhydrolase, Lp-PLA2 is able to hydrolyze the acetyl group at the sn-2 position so that catalyzing the degradation of PAF into substance without activity and finally obtain the biologically inactive products LYSO-PAF and acetate. Moreover, Lp-PLA2 can also act as a calcium-independent serine lipase to hydrolyze the sn-2 fatty acids of oxidized phospholipids within modified low-density lipoprotein specifically and finally generate oxidized fatty acids and lysophosphatidylcholine which have great proinflammatory effects for the initiation and progression of atheroma. In summary, Lp-PLA2 is a high-efficient biomarker for the cardiovascular disease.
Lp-PLA2 Marker of Coronary Heart Disease
Coronary Heart Disease (CHD) is the number one disease cause of death in recent years which results from coronary atherosclerosis. Compared with the lowest quintile, a twofold greater risk of CHD can be observed for patients in the highest quintile of Lp-PLA2 levels. There are also some advantages of Lp-PLA2 to be served as the biomarker for cardiovascular disease. Firstly, the Lp-PLA2 level is independent of insulin resistance. Secondly, the high specificity for vascular inflammation and minimal bio-variation make Lp-PLA2 superior to other inflammatory markers. Some studies have shown that Lp-PLA2 is not a great biomarker for the assessment of long-term cardiovascular disease risk when measured shortly after the acute event but can be served as the high-efficient independent predictor when measured at later time points. In this case, Lp-PLA2 is the biomarker with huge potential for cardiovascular disease.
Fig.1 The putative proatherogenic effects of Lp-PLA2 in atheroma.
Lp-PLA2 Marker of Stroke and TIA
Stroke is a medical phenomenon which is caused by the poor blood flow to the brain and results in cell death. Transient ischemic attack (TIA) is the precursor of stroke which is caused by the small clots occlusion of blood and occurs within a few hours or days before the stroke. A lot of studies have shown that Lp-PLA2 is an independent risk predictor of stroke and TIAs and individuals with the increased level of Lp-PLA2 have an 11-fold higher incidence of stroke than individuals with lower Lp-PLA2. In this case, Lp-PLA2 is a good biomarker for the diagnosis of stroke and TIA.
IVD Antibody Development Services for Lp-PLA2 Marker
IVD antibodies are essential elements of commercial antibody-based in vitro diagnostic kits. Creative Biolabs has built an IVD platform for not only the development of high-quality antibodies for diagnostic use but also antibody & antigen conjugation and IVD kit development. Thus, we can help develop polyclonal, monoclonal, and recombinant antibodies against Lp-PLA2 marker to aid in the development of IVD kits based on different immunoassay formats, such as latex-enhanced immunoturbidimetry, lateral flow immunochromatographic assays, and ELISA.
Supported by our highly specialized scientists and advanced platform, we are confident in providing services with the best quality and the most competitive prices. If you are interested in our services, contact us for more information.
For Research Use Only.
